# Illumina, Inc. (ILMN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $25.35B  
**Price:** $162.47 (+1.52%)

> Illumina, Inc. is a life sciences and diagnostics company that develops, manufactures, and markets tools and integrated systems for the analysis of genetic material. Its primary focus is on next-generation sequencing technologies, providing high-throughput and lower-throughput sequencing instruments, consumables, and related services used across research, clinical, and applied markets. Illumina’s platforms enable applications such as whole-genome sequencing, targeted sequencing, and genetic screening in areas including oncology, rare disease, reproductive health, infectious disease, and agriculture. The company also offers microarray products for cost-effective, focused genetic analysis, along with software, bioinformatics, and cloud-based tools that support data processing and interpretation. In addition, Illumina provides sequencing and microarray services, instrument monitoring, training, and consulting to laboratories and institutions worldwide. Founded in 1998 and headquartered in San Diego, California, Illumina plays a central role in enabling genomic research and clinical diagnostics by supplying core infrastructure that underpins many modern genomics applications.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $4.34B | $2.87B | $807M | $850M | $5.45 |
| 2024 | $4.37B | $2.86B | -$833M | -$1.22B | $-7.69 |
| 2023 | $4.50B | $2.74B | -$1.07B | -$1.16B | $-7.34 |
| 2023 | $4.58B | $2.97B | -$4.18B | -$4.40B | $-28.00 |
| 2022 | $4.53B | $3.15B | -$123M | $762M | $5.04 |
| 2021 | $3.24B | $2.20B | $580M | $656M | $4.45 |
| 2019 | $3.54B | $2.47B | $985M | $1.00B | $6.74 |
| 2018 | $3.33B | $2.30B | $883M | $826M | $5.56 |
| 2017 | $2.75B | $1.83B | $606M | $726M | $4.92 |
| 2017 | $2.40B | $1.67B | $587M | $463M | $3.07 |
| 2016 | $2.22B | $1.55B | $613M | $462M | $3.10 |
| 2014 | $1.86B | $1.30B | $515M | $353M | $2.37 |
| 2013 | $1.42B | $912M | $134M | $125M | $0.90 |
| 2012 | $1.15B | $774M | $201M | $151M | $1.13 |
| 2012 | $1.06B | $709M | $199M | $87M | $0.62 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $6.64B | $3.92B | $2.72B | — | — |
| 2024 | $6.30B | $3.93B | $2.37B | — | — |
| 2023 | $10.11B | $4.37B | $5.75B | — | — |
| 2023 | $12.25B | $5.65B | $6.60B | — | — |
| 2022 | $15.22B | $4.48B | $10.74B | — | — |
| 2021 | $7.58B | $2.89B | $4.69B | — | $673M |
| 2019 | $7.32B | $2.70B | $4.61B | — | $1.14B |
| 2018 | $6.96B | $3.20B | $3.76B | $1.14B | $890M |
| 2017 | $5.26B | $2.51B | $2.75B | $1.23B | $1.18B |
| 2017 | $4.28B | $2.08B | $2.20B | $735M | $1.06B |
| 2016 | $3.69B | $1.84B | $1.85B | $769M | $1.02B |
| 2014 | $3.34B | $1.88B | $1.46B | $636M | $987M |
| 2013 | $3.02B | $1.49B | $1.53B | $712M | — |
| 2012 | $2.57B | $1.25B | $1.32B | $434M | — |
| 2012 | $2.20B | $1.12B | $1.08B | $303M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $1.08B | $148M | $931M |
| 2024 | $837M | $128M | $709M |
| 2023 | $478M | $195M | $283M |
| 2023 | $392M | $286M | $106M |
| 2022 | $545M | $208M | $337M |
| 2021 | $1.08B | $189M | $891M |
| 2019 | $1.05B | $209M | $842M |
| 2018 | $1.14B | $296M | $846M |
| 2017 | $875M | $310M | $565M |
| 2017 | $779M | $260M | $519M |
| 2016 | $786M | $143M | $643M |
| 2014 | $501M | $106M | $395M |
| 2013 | $386M | $79M | $307M |
| 2012 | $292M | $69M | $223M |
| 2012 | $358M | $78M | $280M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ILMN)